Prescription Charges and Tuberculosis
SIR,-I am extremely disturbed to note that pulmonary tuberculosis is not included in the list of conditions for which drugs will be prescribed without a prescription charge.
I understand that it is, however, included in the list of conditions where an appropriate charge for a period of three months or a year might be made. I consider, however, that any charge to a patient on chemotherapy for pulmonary tuberculosis will discourage many patients from taking chemotherapy, which is in all conscience difficult enough to administer to patients at home as it is. The end result of this, of course, will be relapse, further admission of patients to hospital, recurrence of positive sputum, and the spread of the disease with increasing cost to the National Health Service, I make a strong plea, therefore, for every chest physician to write to his Member of Parliament to protest about this before it is too late. " Normal " Temperature SIR,-In view of the national change from degrees Fahrenheit to degrees Centigrade it seems likely that the clinical thermometer will receive a new scale. Would not this be a good opportunity to get rid, once and for all, of that little red line which suggests that temperatures above or below it are abnormal ?
There has long been good evidence that this arbitrary " normal " temperature is misleading. ' Price of Blood SIR,-A document by Cooper and Culyer,1 of the University of Exeter, setting out the arguments for the purchase of blood for transfusion, has recently been published (see also leading article, p. 129). The simple economic law of supply and demand cannot, of course, be denied (although the same argument can be extended to the supply of kidneys for transplantation). However, the authors of this lengthy paper have completely ignored the outstanding hazard of commercially supplied blood-namely, the risk of post-transfusion hepatitis. Thus while it is easy to dismiss emotional and altruistic motives for blood donation by healthy adults, it would be a mistake to accept that purchased blood would achieve the same criteria of probable low infectivity so far as the virus of hepatitis is concerned. Experience elsewhere indicates that the risk of posttransfusion hepatitis is very much greater when commercial sources are used, the reason being that complete reliance must be placed on the verbal history of past infections and current health of the donor. No satisfactory laboratory tests are available at present for the detection of asymptomatic and chronic carriers of the hepatitis virus. The integrity of the potential purveyor of blood must therefore be assumed. Payment for blood has been known to attract sometimes an undesirable section of the population, notably narcotic addicts (whose risk of serum hepatitis is notoriously high), chronic alcoholics, and others. Furthermore, experience has shown that when potential donors were turned down by some blood banks on health grounds they soon managed to sell their blood elsewhere. Consequently as long as the blood bank must rely upon accurate medical history and the truthfulness of the potential donor this risk must be taken into consideration.
The figures for post-transfusion hepatitis, both in the icteric and anicteric form, published from some centres in the United States, Germany, and Japan, are remarkably high. In a recent study the overall attack rate of post-transfusion hepatitis was found to be 14%,' but a very much higher incidence has also been reported.' The overall mortality rate can be as high as 28%.' In 1963, in the United States, about 1.8 million patients were transfused, and it has been estimated that the incidence of clinical transfusion hepatitis was 30,000 cases with nearly 3,600 deaths. No account was taken of the incidence of anicteric hepatitis, and, in general, the accepted ratio is 1 overt case for at least 10 actual infections, although in 1965 it was estimated that the ratio of anicteric to icteric hepatitis after blood transfusion could be greater than 100: 1 (based on a small number of patients).' Casting aside for the moment the economics in terms of mortality and morbidity, it would have been quite a useful exercise in economics to calculate the cost of treatment of patients with hepatitis. This indeed has been done in one reported series from the United States.6 The " average " patient suffering from post-transfusion hepatitis required hospital treatment for 35 days, incurring hospital costs of £300 to £670.
There 
